English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA regulatory class of human T cells descends from two different origins, one that relates to autoimmunity and one that relates to protective immunity, according to a new study led by Children’s Hospital of Philadelphia (CHOP). The findings, published today in Science Immunology, could pave the way for new treatments for autoimmune diseases that target the immune system selectively.
Tag: basic science research
Pushing the Boundaries of Moore’s Law: How Can Extreme UV Light Produce Tiny Microchips?
Some analysts say that the end of Moore’s Law is near, but Patrick Naulleau, the director of Berkeley Lab’s Center for X-Ray Optics (CXRO), says that it could be decades before the modern chip runs out of room for improvement, thanks to advances in materials and instrumentation enabled by the CXRO.
Albert Einstein College of Medicine Awarded $5 Million for Research on Intellectual and Developmental Disabilities
Albert Einstein College of Medicine has received a five-year, $5 million grant from the National Institutes of Health (NIH) to support the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (RFK IDDRC), which has been at the forefront of research on normal and abnormal brain development for more than 50 years.
Journalists: Be our guest at the 2021 Virtual ACSM Research Conference
Gain story ideas and learn about cutting-edge science at ACSM’s comprehensive sports medicine and exercise science conference that covers the science, practice, public health and policy aspects of sports medicine, exercise science and physical activity.
Successful DNA replication in cyanobacteria depends on the circadian clock
A new study from the University of Chicago has found that the photosynthetic bacterium Synechococcus elongatus uses a circadian clock to precisely time DNA replication, and that interrupting this circadian rhythm prevents replication from completing and leaves chromosomes unfinished overnight.
Harrington Discovery Institute Announces New Fund to Advance Breakthrough Discoveries into Novel Treatments
The transatlantic, not-for-profit medical accelerator, Harrington Discovery Institute (HDI) at University Hospitals, has collaborated with leading venture investor, Advent Life Sciences (‘Advent’) in the launch of the Advent-Harrington Impact Fund. Advent’s new impact fund, structured alongside Advent Life Sciences Fund III, brings a total of $215 million to advance breakthrough discoveries into novel treatments for the benefit of patients and society.